200 related articles for article (PubMed ID: 35798468)
21. Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review.
Saneeymehri SS; Markey KR; Mahipal A
J Oncol Pharm Pract; 2016 Jun; 22(3):552-5. PubMed ID: 25852107
[TBL] [Abstract][Full Text] [Related]
22. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
23. Fluoropyrimidine Cardiotoxicity: Incidence, Outcomes, and Safety of Rechallenge.
Vater LB; Lefebvre B; Turk A; Clasen SC
Curr Oncol Rep; 2022 Jul; 24(7):943-950. PubMed ID: 35347593
[TBL] [Abstract][Full Text] [Related]
24. Capecitabine Versus Continuous Infusion Fluorouracil for the Treatment of Advanced or Metastatic Colorectal Cancer: a Meta-analysis.
Wu Z; Deng Y
Curr Treat Options Oncol; 2018 Nov; 19(12):77. PubMed ID: 30483908
[TBL] [Abstract][Full Text] [Related]
25. Risk Factors of Fluoropyrimidine Induced Cardiotoxicity among Cancer Patients: A Systematic Review and Meta-analysis.
Li C; Ngorsuraches S; Chou C; Chen L; Qian J
Crit Rev Oncol Hematol; 2021 Jun; 162():103346. PubMed ID: 33930532
[TBL] [Abstract][Full Text] [Related]
26. Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity.
Deboever G; Hiltrop N; Cool M; Lambrecht G
Clin Colorectal Cancer; 2013 Mar; 12(1):8-14. PubMed ID: 23102544
[TBL] [Abstract][Full Text] [Related]
27. 5-FU Cardiotoxicity: Vasospasm, Myocarditis, and Sudden Death.
More LA; Lane S; Asnani A
Curr Cardiol Rep; 2021 Feb; 23(3):17. PubMed ID: 33537861
[TBL] [Abstract][Full Text] [Related]
28. 5-Fluorouracil, capecitabine and vasospasm: a scoping review of pathogenesis, management options and future research considerations.
Teperikidis E; Boulmpou A; Charalampidis P; Tsavousoglou C; Giannakoulas G; Papadopoulos CE; Vassilikos V
Acta Cardiol; 2022 Feb; 77(1):1-13. PubMed ID: 33683181
[TBL] [Abstract][Full Text] [Related]
29. Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment.
Molteni LP; Rampinelli I; Cergnul M; Scaglietti U; Paino AM; Noonan DM; Bucci EO; Gottardi O; Albini A
Breast J; 2010; 16 Suppl 1():S45-8. PubMed ID: 21050310
[TBL] [Abstract][Full Text] [Related]
30. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
Van Cutsem E; Twelves C; Cassidy J; Allman D; Bajetta E; Boyer M; Bugat R; Findlay M; Frings S; Jahn M; McKendrick J; Osterwalder B; Perez-Manga G; Rosso R; Rougier P; Schmiegel WH; Seitz JF; Thompson P; Vieitez JM; Weitzel C; Harper P;
J Clin Oncol; 2001 Nov; 19(21):4097-106. PubMed ID: 11689577
[TBL] [Abstract][Full Text] [Related]
31. Incidence of capecitabine-related cardiotoxicity in different treatment schedules of metastatic colorectal cancer: A retrospective analysis of the CAIRO studies of the Dutch Colorectal Cancer Group.
Kwakman JJ; Simkens LH; Mol L; Kok WE; Koopman M; Punt CJ
Eur J Cancer; 2017 May; 76():93-99. PubMed ID: 28286287
[TBL] [Abstract][Full Text] [Related]
32. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors.
Polk A; Vaage-Nilsen M; Vistisen K; Nielsen DL
Cancer Treat Rev; 2013 Dec; 39(8):974-84. PubMed ID: 23582737
[TBL] [Abstract][Full Text] [Related]
33. An unusual case of acute myopericarditis after the first dose of capecitabine: Need for new cardioprotective strategies and risk stratification.
Meter M; Gavran I; Bajo D; Duplancic D
Int J Clin Pharmacol Ther; 2021 Dec; 59(12):775-779. PubMed ID: 34503643
[TBL] [Abstract][Full Text] [Related]
34. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.
Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Frederix GWJ; Kienhuis E; Creemers GJ; Baars A; Dezentjé VO; Imholz ALT; Jeurissen FJF; Portielje JEA; Jansen RLH; Hamberg P; Ten Tije AJ; Droogendijk HJ; Koopman M; Nieboer P; van de Poel MHW; Mandigers CMPW; Rosing H; Beijnen JH; Werkhoven EV; van Kuilenburg ABP; van Schaik RHN; Mathijssen RHJ; Swen JJ; Gelderblom H; Cats A; Guchelaar HJ; Schellens JHM
Lancet Oncol; 2018 Nov; 19(11):1459-1467. PubMed ID: 30348537
[TBL] [Abstract][Full Text] [Related]
35. Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine.
Jensen SA; Sørensen JB
Cancer Chemother Pharmacol; 2006 Oct; 58(4):487-93. PubMed ID: 16418875
[TBL] [Abstract][Full Text] [Related]
36. Fluoropyrimidine-associated cardiotoxicity: revisited.
Saif MW; Shah MM; Shah AR
Expert Opin Drug Saf; 2009 Mar; 8(2):191-202. PubMed ID: 19309247
[TBL] [Abstract][Full Text] [Related]
37. Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy.
Li C; Chen L; Chou C; Ngorsuraches S; Qian J
Cardiovasc Toxicol; 2022 Feb; 22(2):130-140. PubMed ID: 34792740
[TBL] [Abstract][Full Text] [Related]
38. Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines.
Ransom D; Wilson K; Fournier M; Simes RJ; Gebski V; Yip D; Tebbutt N; Karapetis CS; Ferry D; Gordon S; Price TJ
Ann Oncol; 2014 Jan; 25(1):117-21. PubMed ID: 24299960
[TBL] [Abstract][Full Text] [Related]
39. Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil.
Frickhofen N; Beck FJ; Jung B; Fuhr HG; Andrasch H; Sigmund M
Ann Oncol; 2002 May; 13(5):797-801. PubMed ID: 12075751
[TBL] [Abstract][Full Text] [Related]
40. Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma.
Twelves C; Boyer M; Findlay M; Cassidy J; Weitzel C; Barker C; Osterwalder B; Jamieson C; Hieke K;
Eur J Cancer; 2001 Mar; 37(5):597-604. PubMed ID: 11290435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]